{
  "m_q": {
    "target_metric": "List of protein sites (phosphorylation or acetylation sites) that are hyperactivated in CNV-high endometrioid samples and are targeted by FDA-approved drugs",
    "filters": [
      "Histologic_type = 'Endometrioid'",
      "CNV_class = 'CNV_HIGH' (or similar high CNV classification)",
      "Hyperactivation defined by significant positive FoldChange in phospho/acetyl sites with appropriate statistical thresholds (e.g., FDR < 0.05, FoldChange > threshold)"
    ],
    "grouping_variables": [
      "ID (protein site identifier)",
      "Gene"
    ],
    "output_cardinality": "list",
    "sub_questions": [
      "Which samples are CNV-high endometrioid?",
      "Which protein sites are hyperactivated in these samples?",
      "Which of those sites correspond to genes targeted by FDA-approved drugs?",
      "What drugs target those genes?"
    ]
  },
  "m_s": {
    "sources": [
      "1-s2.0-S0092867420301070-mmc1.xlsx",
      "1-s2.0-S0092867420301070-mmc6__B-SE phospho site between Serou",
      "1-s2.0-S0092867420301070-mmc6__C-SE scetyl site between Serous",
      "1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs",
      "hyperactivated.csv"
    ],
    "join_keys": [
      {
        "left_source": "1-s2.0-S0092867420301070-mmc1.xlsx",
        "right_source": "hyperactivated.csv",
        "left_column": "idx",
        "right_column": "sample_id",
        "join_type": "inner"
      },
      {
        "left_source": "1-s2.0-S0092867420301070-mmc6__B-SE phospho site between Serou",
        "right_source": "1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs",
        "left_column": "Gene",
        "right_column": "gene_name",
        "join_type": "inner"
      },
      {
        "left_source": "1-s2.0-S0092867420301070-mmc6__C-SE scetyl site between Serous",
        "right_source": "1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs",
        "left_column": "Gene",
        "right_column": "gene_name",
        "join_type": "inner"
      }
    ],
    "schema_conflicts": [
      "Different naming conventions for CNV classification (CNV_class vs CNV_idx)",
      "Protein site IDs in phospho/acetyl sheets contain gene and site info (e.g., 'AAAS-S495') while hyperactivated.csv has only protein names",
      "Multiple drug entries per gene in FDA sheet"
    ],
    "column_mappings": {
      "signedlogp.ac": "signedlogp.acetyl",
      "logfdr.phos": "logFDR.phos"
    }
  },
  "m_u": {
    "unit_annotations": {
      "FoldChange.protein": "log2 fold change",
      "FoldChange.phos": "log2 fold change",
      "FoldChange.acetyl": "log2 fold change",
      "FoldChange.rna": "log2 fold change",
      "pval.*": "p-value",
      "FDR.*": "false discovery rate",
      "CNV_DEL": "copy number deletion score",
      "CNV_AMP": "copy number amplification score"
    },
    "scale_issues": [
      "FoldChange values appear to be on different scales across datasets",
      "CNV_class is categorical while CNV_idx is numeric",
      "Some p-values are extremely small (e.g., 1.9698205776291e-05)"
    ],
    "cross_source_conflicts": [
      "hyperactivated.csv lists protein names but phospho/acetyl sheets use site-specific IDs",
      "CNV classification criteria not explicitly defined across sources"
    ]
  },
  "m_f": {
    "has_header": true,
    "delimiter": ",",
    "encoding": "utf-8",
    "sentinel_values": [
      "NA",
      "N/A",
      "",
      "Cannot be determined"
    ],
    "expected_columns": 10,
    "expected_rows": 0,
    "file_format": "csv",
    "format_notes": [
      "Excel files contain multiple sheets with different data",
      "Phospho and acetyl site IDs combine gene and modification site (e.g., 'AAAS-S495')",
      "Some columns have spaces in names (e.g., 'CIBERSORT_B _cells _naive')"
    ]
  },
  "m_c": {
    "constraints": [
      "Only endometrioid histology samples",
      "Only CNV-high samples (need to define threshold from CNV_class or CNV_idx)",
      "Statistical significance: FDR < 0.05 for phospho/acetyl sites",
      "Hyperactivation: positive FoldChange in phospho/acetyl sites",
      "Must have corresponding FDA-approved drug targeting the gene"
    ],
    "derived_filters": [
      "Filter mmc1 for Histologic_type = 'Endometrioid'",
      "Filter mmc1 for CNV_class indicating high CNV (or CNV_idx > threshold)",
      "Filter phospho/acetyl sheets for FDR.phos/FDR.acetyl < 0.05 and FoldChange.phos/FoldChange.acetyl > 0",
      "Filter FDA sheet for unique gene-drug pairs"
    ],
    "statistical_tests": [
      "Differential expression/phosphorylation/acetylation tests already performed in provided sheets",
      "Need to apply multiple testing correction (FDR already provided)"
    ],
    "output_format_requirements": [
      "List of protein sites with: ID, Gene, Modification type, FoldChange, FDR, Associated drug names",
      "Should include both phospho and acetyl sites meeting criteria"
    ]
  },
  "raw_text": "```json\n{\n    \"M_Q\": {\n        \"target_metric\": \"List of protein sites (phosphorylation or acetylation sites) that are hyperactivated in CNV-high endometrioid samples and are targeted by FDA-approved drugs\",\n        \"filters\": [\"Histologic_type = 'Endometrioid'\", \"CNV_class = 'CNV_HIGH' (or similar high CNV classification)\", \"Hyperactivation defined by significant positive FoldChange in phospho/acetyl sites with appropriate statistical thresholds (e.g., FDR < 0.05, FoldChange > threshold)\"],\n        \"grouping_variables\": [\"ID (protein site identifier)\", \"Gene\"],\n        \"output_cardinality\": \"list\",\n        \"sub_questions\": [\"Which samples are CNV-high endometrioid?\", \"Which protein sites are hyperactivated in these samples?\", \"Which of those sites correspond to genes targeted by FDA-approved drugs?\", \"What drugs target those genes?\"]\n    },\n    \"M_S\": {\n        \"sources\": [\"1-s2.0-S0092867420301070-mmc1.xlsx\", \"1-s2.0-S0092867420301070-mmc6__B-SE phospho site between Serou\", \"1-s2.0-S0092867420301070-mmc6__C-SE scetyl site between Serous\", \"1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs\", \"hyperactivated.csv\"],\n        \"join_keys\": [\n            {\"left_source\": \"1-s2.0-S0092867420301070-mmc1.xlsx\", \"right_source\": \"hyperactivated.csv\", \"left_column\": \"idx\", \"right_column\": \"sample_id\", \"join_type\": \"inner\"},\n            {\"left_source\": \"1-s2.0-S0092867420301070-mmc6__B-SE phospho site between Serou\", \"right_source\": \"1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs\", \"left_column\": \"Gene\", \"right_column\": \"gene_name\", \"join_type\": \"inner\"},\n            {\"left_source\": \"1-s2.0-S0092867420301070-mmc6__C-SE scetyl site between Serous\", \"right_source\": \"1-s2.0-S0092867420301070-mmc6__G-FDA approved drugs\", \"left_column\": \"Gene\", \"right_column\": \"gene_name\", \"join_type\": \"inner\"}\n        ],\n        \"schema_conflicts\": [\"Different naming conventions for CNV classification (CNV_class vs CNV_idx)\", \"Protein site IDs in phospho/acetyl sheets contain gene and site info (e.g., 'AAAS-S495') while hyperactivated.csv has only protein names\", \"Multiple drug entries per gene in FDA sheet\"],\n        \"column_mappings\": {\"signedlogp.ac\": \"signedlogp.acetyl\", \"logfdr.phos\": \"logFDR.phos\"}\n    },\n    \"M_U\": {\n        \"unit_annotations\": {\"FoldChange.protein\": \"log2 fold change\", \"FoldChange.phos\": \"log2 fold change\", \"FoldChange.acetyl\": \"log2 fold change\", \"FoldChange.rna\": \"log2 fold change\", \"pval.*\": \"p-value\", \"FDR.*\": \"false discovery rate\", \"CNV_DEL\": \"copy number deletion score\", \"CNV_AMP\": \"copy number amplification score\"},\n        \"scale_issues\": [\"FoldChange values appear to be on different scales across datasets\", \"CNV_class is categorical while CNV_idx is numeric\", \"Some p-values are extremely small (e.g., 1.9698205776291e-05)\"],\n        \"cross_source_conflicts\": [\"hyperactivated.csv lists protein names but phospho/acetyl sheets use site-specific IDs\", \"CNV classification criteria not explicitly defined across sources\"]\n    },\n    \"M_F\": {\n        \"has_header\": true,\n        \"delimiter\": \",\",\n        \"encoding\": \"utf-8\",\n        \"sentinel_values\": [\"NA\", \"N/A\", \"\", \"Cannot be determined\"],\n        \"expected_columns\": 10,\n        \"file_format\": \"csv\",\n        \"format_notes\": [\"Excel files contain multiple sheets with different data\", \"Phospho and acetyl site IDs combine gene and modification site (e.g., 'AAAS-S495')\", \"Some columns have spaces in names (e.g., 'CIBERSORT_B _cells _naive')\"]\n    },\n    \"M_C\": {\n        \"constraints\": [\"Only endometrioid histology samples\", \"Only CNV-high samples (need to define threshold from CNV_class or CNV_idx)\", \"Statistical significance: FDR < 0.05 for phospho/acetyl sites\", \"Hyperactivation: positive FoldChange in phospho/acetyl sites\", \"Must have corresponding FDA-approved drug targeting the gene\"],\n        \"derived_filters\": [\"Filter mmc1 for Histologic_type = 'Endometrioid'\", \"Filter mmc1 for CNV_class indicating high CNV (or CNV_idx > threshold)\", \"Filter phospho/acetyl sheets for FDR.phos/FDR.acetyl < 0.05 and FoldChange.phos/FoldChange.acetyl > 0\", \"Filter FDA sheet for unique gene-drug pairs\"],\n        \"statistical_tests\": [\"Differential expression/phosphorylation/acetylation tests already performed in provided sheets\", \"Need to apply multiple testing correction (FDR already provided)\"],\n        \"output_format_requirements\": [\"List of protein sites with: ID, Gene, Modification type, FoldChange, FDR, Associated drug names\", \"Should include both phospho and acetyl sites meeting criteria\"]\n    }\n}\n```",
  "system_name": "deepseek",
  "extraction_time_s": 25.235305309295654,
  "token_usage": {
    "input_tokens": 20163,
    "output_tokens": 1230
  }
}